Review Article

What lessons can be learned from the launch of generic clopidogrel?

Published in: Volume 1 / Year 2012 / Issue 2
Author(s): ,
Page: 58-68

Author byline as per print journal: Christoph Baumgärtel1, MD; Brian Godman2,3,4, BSc, PhD; Rickard E Malmstrom5, MD, PhD; Morten Andersen6, MD, PhD; Mohammed Abuelkhair7, PharmD; Shajahan Abdu7, MD; Marion Bennie8,9, MSc;… Read More »

A review of patient perspectives on generics substitution: what are the challenges for optimal drug use

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 28-32

Author byline as per print journal: Helle Håkonsen, MScPharm, PhD; Else-Lydia Toverud, MScPharm, PhD Introduction: With a few exceptions, generic drug use has been promoted in western countries by allowing pharmacists to… Read More »

European payer initiatives to reduce prescribing costs through use of generics

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 22-7

Author byline as per print journal:  Brian Godman1,2,3, BSc, PhD; Bjorn Wettermark1,4, MSc, PhD; Iain Bishop5, BSc; Thomas Burkhardt6, MSc; Jurij Fürst7, PhD; Kristina Garuoliene8, MD; Ott Laius9, MScPharm; Jaana E Martikainen10,… Read More »

A patient-centred paradigm for the biosimilars market

Published in: Volume 1 / Year 2012 / Issue 1
Author(s): ,
Page: 17-21

Abstract:  The advent of similar biological medicinal products or ‘biosimilars’ in Europe in the 2000s has led to development of a global biosimilars market and regulatory frameworks designed specifically for… Read More »

Biologicals and biosimilars: a review of the science and its implications

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 13-6

Abstract:  Biopharmaceuticals are medicines whose active drug substance is made by living cells. Copies of these drugs, called biosimilars, are not identical to their reference drug and therefore specific regulatory… Read More »

A review of generic medicine pricing in Europe

Published in: Volume 1 / Year 2012 / Issue 1
Author(s):
Page: 08-12

Introduction: Switching from originator products to generic equivalents is a key method used by governments to reduce costs and keep their healthcare systems sustainable. The aim of this article is to review… Read More »

Does L-Thyroxine meet the criteria of a narrow therapeutic index drug (NTID) according to Bioequivalence-guideline of the European Medicines Agency?

Author(s):

Aim: This review discusses pros and cons of whether L-Thyroxine should be regarded as a narrow therapeutic Index drug (NTID). Methodology: A search in PubMed was performed in March/April 2014.… Read More »

Protein heterogeneity and the immunogenicity of biotherapeutics

Author(s):

Introduction The human genome (HG) is comprised of ~ 20,000 open reading frame (ORF) genes; however the human proteome (HP) is orders of magnitude greater due to alternate ORF gene… Read More »

Page 4 of 4 « Previous1 2 3 4
Go Back Print